The pharmacokinetics of dilevalol in renal impairment.
Dilevalol, 200 mg, was administered orally as seven daily doses to three groups of six participants, with differing degrees of renal impairment. Values of Cmax, Tmax, half-life or renal elimination did not significantly change with decreased renal function. Values of area under the plasma concentration-time curves and pre-dose concentrations tended to increase with renal impairment and there was a significant, if small, correlation between these and glomerular filtration rate. The practical clinical consequences of these results is that impairment is not likely to be associated with significant accumulation of dilevalol.
Kelly
J G
JG
Institute of Biopharmaceuticals, Athlone, Ireland.
Laher
M S
MS
Donohue
J
J
Doyle
G D
GD
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005260:Female; D005919:Glomerular Filtration Rate; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D007741:Labetalol / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012016:Reference Values
D007741:Labetalol